Healthy adults
Conditions
Interventions
Daily ingestion 75 g of the potato1 for 8 weeks.
Daily ingestion 75 g of the potato2 for 8 weeks.
Sponsors
Hokkaido Information University
Sapporo Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects who agree to participate in this study with a written informed consent. 2. Subjects with a minor ailment.
Exclusion criteria
Exclusion criteria: 1. Subjects who are under physician's advice, treatment, and/or medication for schizophrenia, depression, mania, neurological disorders, and/or sleep disorders. 2. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 3. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 4. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 5. Subjects with severe anemia. 6. Pre- or post-menopausal women complaining of obvious physical changes. 7. Subjects who are at risk of having allergic reactions to drugs or foods especially based on potatoes, Betulaceae, Poaceae. 8. Subjects who regularly take medicine, functional foods, and/or supplements which would affect sleep and/or stress. 9. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 10. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study. 11. Pregnant or lactating women or women who expect to be pregnant during this study. 12. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 13. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood test after 8 weeks of ingestion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intestinal flora, heart rate variability, electroencephalogram during sleeping, sleeping record, urinary metabolites, urinary 8OHdG, 1,5-AG, VAS questionnaire assessed fatigue, questionnaire about subjects' background information. | — |
Countries
Japan
Contacts
Public ContactJun NISHIHIRA
Hokkaido Information University Health Information Science Center
Outcome results
None listed